Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
81 hedge funds and large institutions have $139M invested in Marinus Pharmaceuticals, Inc in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 36 increasing their positions, 19 reducing their positions, and 20 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 19
41% more capital invested
Capital invested by funds: $98.4M → $139M (+$40.7M)
2% less call options, than puts
Call options by funds: $5.87M | Put options by funds: $5.96M
10% less funds holding
Funds holding: 90 → 81 (-9)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
45% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.74M |
| 2 |
TA
Teachers Advisors
New York
|
+$1.97M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.57M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.39M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$943K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JG
Jefferies Group
New York
|
-$4.88M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.54M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.51M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.44M |
| 5 |
Millennium Management
New York
|
-$906K |
MRNS Hedge Fund Activity: Q1 2019 in Review
81 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2019, worth a combined $139M — up 41% from $98.4M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of MRNS and 11 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 36 added.
The largest buyer was BlackRock, adding an estimated $2.74M. The largest seller was Jefferies Group, exiting entirely with an estimated $4.88M sold.
- 81 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2019, down from 90 in Q4 2018.
- Funds reported $139M of Marinus Pharmaceuticals, Inc stock for Q1 2019, up 41% quarter-over-quarter.
- 11 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2019 and 20 closed out, a net change of -9 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2019 was BlackRock, an estimated $2.74M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2019 was Jefferies Group, an estimated $4.88M sold.
Based on aggregated 13F filings for Q1 2019.